Genome edit­ing prod­ucts: FDA rec­om­mends at least 15 years of fol­low-up af­ter clin­i­cal tri­als

As In­tel­lia re­cent­ly un­veiled its lat­est promis­ing da­ta around one in a se­ries of po­ten­tial­ly game-chang­ing gene ther­a­pies, the FDA on Tues­day sought to fur­ther …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.